Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The investigators will enroll continuous ambulatory peritoneal dialysis (CAPD) patients with
hyperuricemia and randomly divide them into two groups, treated with Febuxostat and placebo
respectively. After 3 years of following up, cardiovascular events, all cause mortality,
cardiovascular mortality and non-fatal cardiovascular events are collected and recorded. The
difference of cardiovascular events, all cause mortality and non-fatal cardiovascular event
rate will be analyzed.